Extended Data Fig. 6: Validation of inference using seroprevalence data.
From: Burden and characteristics of COVID-19 in the United States during 2020
(a) – (b) Comparison between the inferred percentage of cumulative infections and seroprevalence at the state level adjusted for antibody waning. Seroprevalence data adjusted using a maximum monthly attenuation rate of 17.5% (a) and 15% (b) are included in the analysis. (c) – (d) Comparison between the model-generated seroprevalence and observed seroprevalence in 10 locations (c) and at the state level (d). (e) – (f) Comparison between the inferred percentage of cumulative infections and seroprevalence in 10 locations (e) and at the state level (f) adjusted for antibody waning using lower sensitivity and specificity. Distributions are obtained from n = 100 ensemble members. Centre and whiskers show median and 95% CIs. Color indicates the sample collection date for each location.
